Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study

por Kuemmel, Sherko, Tondini, Carlo A., Abraham, Jacinta, Nowecki, Zbigniew, Itrych, Bartosz, Hitre, Erika, Karaszewska, Bogusława, Juárez-Ramiro, Alejandro, Morales-Vásquez, Flavia, Pérez-García, Jose Manuel, Cardona-Huerta, Servando, Monturus, Estefania, Sequi, Marco, Restuccia, Eleonora, Benyunes, Mark, Martín, Miguel
Publicado 2021